MECHANISMS OF RESISTANCE TO MENIN INHIBITOR THERAPY AND ACUTE MYELOID LEUKAEMIA
With
Dr Rithin Nedumannil,
Consultant Haematologist and PhD Candidate,
Peter MacCallum Cancer Centre,
Austin Health,
Eastern Health,
Royal Melbourne Hospital
Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | June 2025
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
After completing his medical degree at the University of Adelaide, Dr Nedumannil undertook advanced training in clinical and laboratory haematology across Melbourne’s major tertiary centres. He was awarded dual fellowships (FRACP and FRCPA) and went on to complete a subspecialty fellowship in Acute Leukaemia and Myelodysplastic Syndromes at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital in 2024. He also holds a Master of Public Health from the University of New South Wales.
His interest in translational leukaemia research has been shaped by extensive clinical experience and academic work focusing on measurable residual disease, novel fusion genes and treatment resistance in acute leukaemias. His PhD will explore resistance mechanisms to menin inhibitors in acute myeloid leukaemia (AML) using genome-scale technologies including CRISPR screening, RNA sequencing and epigenomic profiling. His research will be conducted over two years at the Cambridge Stem Cell Institute and one year at Peter MacCallum Cancer Centre.
For this work, Dr Nedumannil has been awarded the 2025 Haematology Society of Australia and New Zealand and Leukaemia Foundation New Investigator PhD Scholarship, supporting his goal of translating molecular insights into improved therapeutic strategies for high-risk AML.
Source: Supplied
https://orcid.org/0000-0002-0883-3942
-
Non-invasive tools for CVD screening and monitoring
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
-
Muscle Cell Communication and Repair
Dr. William Roman is a Group Leader at the Australian Regenerative Medicine Institute (ARMI) at Monash University. He obtained his PhD from Paris Descartes University and Freie University of Berlin, focusing on nuclear positioning during skeletal muscle development. Dr. Roman’s research journey has taken him across the globe, including postdoctoral work in Barcelona, tissue engineering in Lisbon, and a brief stint at Stanford University.
At ARMI, Dr. Roman leads innovative research on intercellular communication within muscle organs. His work involves growing human muscles on chips to understand how skeletal muscle cells interact with neurons and tendons. This research aims to develop better models for studying muscle diseases, drug screening, and even applications in cellular agriculture and biorobotics.
-
Dr Dinesh Palipana
RESEARCH IN SPINAL CORD INJURY
@ GRIFFITH UNIVERSITY, QUEENSLAND, AUSTRALIA
